Related references
Note: Only part of the references are listed.Effects of Rasagiline on Olfactory Function in Patients With Parkinson's Disease
Antje Haehner et al.
MOVEMENT DISORDERS (2013)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials
Lawrence W. Elmer
PARKINSONISM & RELATED DISORDERS (2013)
Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
Geraldine H. Petit et al.
PLOS ONE (2013)
Prevalence and Pharmacological Factors Associated With Impulse-Control Disorder Symptoms in Patients With Parkinson Disease
Santiago Perez-Lloret et al.
CLINICAL NEUROPHARMACOLOGY (2012)
Hyposmia in Parkinson's disease
Maria Victoria Alvarez et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2012)
Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2011)
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Lisa M. Shulman et al.
ARCHIVES OF NEUROLOGY (2010)
The D3 dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5
Pei-Chun Chen et al.
JOURNAL OF NEUROCHEMISTRY (2009)
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
Angelo Antonini et al.
LANCET NEUROLOGY (2009)
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
Robert A. Hauser et al.
ARCHIVES OF NEUROLOGY (2006)
Minimal clinically important change on the Unified Parkinson's Disease Rating Scale
Anette Schrag et al.
MOVEMENT DISORDERS (2006)
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Daniel Weintraub et al.
ARCHIVES OF NEUROLOGY (2006)
The therapeutic potential of monoamine oxidase inhibitors
MBH Youdim et al.
NATURE REVIEWS NEUROSCIENCE (2006)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Assessment of cognition in Parkinson's disease
J Marinus et al.
NEUROLOGY (2003)
Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release
PEM Phillips et al.
SYNAPSE (2002)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
